NYSE:NUVB Nuvation Bio Q3 2026 Earnings Date & Estimates $4.57 -0.13 (-2.85%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$4.57 0.00 (-0.02%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nuvation Bio is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Nuvation Bio in Q3 2026Nuvation Bio is expected to post earnings of -$0.1236 per share on revenue of $34.39 million. In the same quarter a year earlier Nuvation Bio reported -$0.16 per share on revenue of $13.12 million. Nuvation Bio last reported on August 6, 2026, posting -$0.15 per share and missing the -$0.1417 consensus estimate. Nuvation Bio has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1236Expected Revenue$34.39 millionPrior-Year EPS-$0.16Prior-Year Revenue$13.12 millionExpected Revenue Growth+162.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.15 (Missed by -$0.0083)Last Quarter Revenue$31.69 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Nuvation Bio Q3 2026 Earnings FAQ When does Nuvation Bio report Q3 2026 earnings? Nuvation Bio (NYSE:NUVB) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Nuvation Bio's Q3 2026 earnings call? Nuvation Bio's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Nuvation Bio? Analysts expect Nuvation Bio to post earnings of -$0.1236 per share for Q3 2026. How much revenue is Nuvation Bio expected to report? The consensus revenue estimate for Nuvation Bio is $34.39 million for Q3 2026. Nuvation Bio Earnings HeadlinesNuvation Bio And 2 More Penny Stocks To WatchOctober 24 at 6:25 PM | finance.yahoo.comNuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026October 21, 2026 | prnewswire.comThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for more than a decade. A federal filing may outline Musk's next major move: an AI network of up to a million satellites powered by the sun. James Altucher says this supplier holds the piece Musk doesn't own. | Paradigm Press (Ad)Nuvation Bio And 2 Penny Stocks To WatchOctober 19, 2026 | finance.yahoo.comNuvation Bio (NUVB) Gets a Buy from CitiOctober 17, 2026 | theglobeandmail.comNuvation Bio (NUVB) Gets a Buy from RBC CapitalOctober 15, 2026 | theglobeandmail.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB), Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors. Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments. The U.S. Food and Drug Administration approved taletrectinib, marketed as Ibtrozi, in 2025 for adults with locally advanced or metastatic ROS1-positive NSCLC. The company expanded its oncology pipeline through the acquisition of AnHeart Therapeutics, which brought taletrectinib and related development capabilities into Nuvation Bio. Nuvation Bio’s activities include clinical development, regulatory work and commercialization efforts intended to serve cancer patients in the United States and international markets. The company was founded by David Hung, M.D., who serves as its president and chief executive officer.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
